TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion
Brief Summary: The purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic.


Options:
A: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction (Within 30 days of randomization)
B: Composite score of any one of the following events occurring 6 months after cardiac surgery: (1) all-cause mortality; (2) myocardial infarction; (3) new onset renal failure requiring dialysis; or (4) new focal neurological deficit (stroke). (Within 6 months after cardiac surgery.)
C: Mortality (90 day)
D: Composite score of any one of the following: (1) all-cause mortality; (2) myocardial infarction; (3) new renal failure requiring dialysis; or (4) new focal neurological deficit (Up to hospital discharge or postoperative day 28 (whichever occurs first))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion
Brief Summary: The purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic.


Options:
A: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction (Within 30 days of randomization)
B: Composite score of any one of the following events occurring 6 months after cardiac surgery: (1) all-cause mortality; (2) myocardial infarction; (3) new onset renal failure requiring dialysis; or (4) new focal neurological deficit (stroke). (Within 6 months after cardiac surgery.)
C: Methodology of the pilot study (up to 30 days)
D: Functional ability (Measured 10 days after surgery + repeated measurement during 90 days after surgery)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage
Brief Summary: The purpose of this academic lead study is to explore the ideal nutritional support strategy for patient with acute severe stroke.


Options:
A: Enteral nutrition (14 days); Intra-abdominal pressure (14 days)
B: Number of ventilator-free days (VFD) (Measured at Day 28); Mortality before hospital discharge, with unassisted breathing (Measured at Days 60 and 90)
C: Length of stay in ICU and length of stay in the hospital. (2 years)
D: Rate of patients with death or major disability (modified Rankin scale score ≥3) (3 months after enrollment)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: At all of the follow-ups, including the worst period (between four and ten weeks), the intervention group reported higher scores than the control group, suggesting in this RCT that adopting the person-centred-care concept was a promising way to improve function and wellbeing in patients with HNC.


Options:
A: The M.D. Anderson Symptom Inventory (MDASI) (Week 5 and week 11); Patient Reported Outcomes Measurement Information System (PROMIS) V 1.0 (Week 5 and week 11); Quality of Life Index (QLI) (Week 5 and week 11); Use of Unscheduled Health Service (Week 11)
B: Health related quality of life (Change from Baseline HRQoL at 6 months)
C: The primary end point of the study was the maximum grade of acute graft versus host (GVH) disease observed in the recipient.
D: Health related quality of life EORTC QLQ-30 EORTC QLQ-35 (Baseline); Health related quality of life EORTC QLQ-30 EORTC QLQ-35 (Four weeks); Health related quality of life EORTC QLQ-30 EORTC QLQ-35 (10 weeks); Health related quality of life EORTC QLQ-30 EORTC QLQ-35 (18 weeks); Health related quality of life EORTC QLQ-30 EORTC QLQ-35 (52 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Analgesia For Positioning Patient With Femur Fracture For Spinal Anaesthesia : Ultrasound-Guided Fascia Iliaca Compartment Block Versus Intravenous Fentanyl
Brief Summary: This study is performed to determine the efficacy of ultrasound-guided fascia iliaca compartment block during positioning for spinal anaesthesia in patient undergoing repair of proximal femur fracture surgery comparing with intravenous fentanyl.


Options:
A: Opiate Requirements (72 hours)
B: Pain scores (For 24 hours after performance the blockade)
C: Respiratory complications (During hospital stay, up to 1 month)
D: Pain score during positioning (Group 1: 20 minutes after intervention (block), Group 2: 5 minutes after intervention (fentanyl))

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Binocular Dig Rush Game Treatment for Amblyopia
Brief Summary: To compare the efficacy of 1 hour/day of binocular game play 5 days per week plus spectacle correction with spectacle correction only, for treatment of amblyopia in children 4 to \<13 years of age.


Options:
A: Mean Change in Amblyopic-eye Visual Acuity (VA) Older Cohort (Baseline and 4 weeks); Mean Visual Acuity (VA) in Amblyopic-eye (Older Cohort) (4 weeks); Mean Change in Amblyopic-eye Visual Acuity (VA) in Older Cohort (Baseline and 8 weeks); Mean Visual Acuity (VA) in Amblyopic-eye (Older Cohort) (8 weeks); Mean Change in Amblyopic-eye Visual Acuity (VA) Younger Cohort (baseline and 4 weeks); Mean Visual Acuity (VA) in Amblyopic-eye (Younger Cohort) (4 weeks); Mean Change in Amblyopic-eye Visual Acuity (VA) in Younger Cohort (Baseline and 8 weeks); Mean Visual Acuity (VA) in Amblyopic-eye (Younger Cohort) (8 weeks)
B: Change from baseline in visual acuity (6 weeks)
C: The primary outcome measure was logMAR visual acuity, measured 6-weekly for 18 weeks in refractive adaptation phase. In occlusion phase measured 2-weekly until no further gains
D: Change in Distance Visual Acuity From Baseline in the Younger Cohort (5 to <13 Years) (Baseline and 16 weeks); Mean Amblyopic Eye Visual Acuity (Younger Cohort) (16 Weeks from baseline); Mean Change in Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years) (Baseline and 16 weeks); Mean Amblyopic-eye Visual Acuity in the Older Cohort (13 to <17 Years) (16 weeks); Distribution of Change in Amblyopic-eye Visual Acuity (Baseline and 16 weeks); Distribution of Amblyopic-eye Visual Acuity (At 16 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Developing Enhanced Prediction Models to Identify Patients at Risk for Hospital Readmission by Collecting Patient-Generated Health Data
Brief Summary: In this study, patients will be prospectively enrolled for data collection to design prediction models that integrate claims data (inpatient, outpatient, and pharmacy), electronic health record data (on clinical, social, and behavioral indicators), and patient-generated activity data. Patients will be randomized to use either a smartphone or a wearable activity tracking device to capture patient-generated health data.


Options:
A: Percentage of Participants With MDI Misuse From Baseline to 30 Days Post-Discharge (1 month)
B: Hospital readmission within 30 days of discharge (30 days)
C: Medicines adherence (Change in adherence from 6 weeks to 10 weeks and 26 weeks); Cost effectiveness (6 months); Operation of the NMS (1 year from first recruited patient)
D: medication(Roflumilas) history taking (16 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Beck scale for suicidal ideation (six months)
B: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)
C: Change in suicidal ideation severity as measured by the Suicidal Ideation Questionnaire - Jr (Screening, 6 weeks, 24 weeks)
D: Change from first investigation in Posttraumatic Symptom Severity at 18 months (Clinician-Administered PTSD Scale; CAPS) (first investigation (t1), after waiting list (3 months, t2), directly after therapy (3 months, t1), 1 year after therapy (15 months, t3))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)
B: Parasuicidal behaviour (intermittent)
C: Clinical Global Impression (CGI): Improvement (1-7): score 3 ( a little better) associated with a hopelessness scale score < 8 (this means that the suicide risk is low)
D: The primary outcome will be the composite outcome of the number of in-patient psychiatric hospitalisations, the number of A& E contacts, and the number of suicidal acts. (At both 12 and 24 months post randomisation.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)
B: Scale for Suicide Ideation Index (SSI) (Over 8 weeks of treatment); Columbia Suicide Severity Rating Scale (C-SSRS): the Suicidal Ideation Scale (8 weeks of treatment)
C: suicidal ideation - Suicidal Ideation Questionnaire-JR (3 month)
D: Client Satisfaction Questionnaire (CSQ) (14 weeks); Cornell Services Index (CSI) (baseline, 14 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)
B: Number of repeated self-harming acts including suicide attempts (change in number of self-harming acts). (Week 0 (baseline), 17, 28, 52.)
C: Deliberate Self-Harm Inventory Youth version (DSHI-Y) (Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended)
D: Estimated Percentage of Participants Making Suicide Attempt During 24-month Follow-up (24 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)
B: Borderline Symptom Checklist (BSL-23) (Changes in scores of BSL-23 before treatment, and at 4, 8, 12 months after starting the treatment)
C: Rate of participant recruitment (1 year); Rate of retention (1 year); Completeness of data entry (1 year); Cost of interventions (1 year); Unexpected costs (1 year)
D: Perceived Stress Scale (PSS) (Week-1(baseline), Week-5 (post-intervention), Week-13 (follow-up))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide
Brief Summary: The purpose of the study is to test a standardized version of brief admission (BA) through randomized controlled trial (RCT). The main objective is to evaluate if BA can serve as a crisis management model for individuals with recurrent self-harm, including suicide attempts and at least three symptoms of Borderline Personality disorder. Participants will be allocated to BA + Treatment as Usual (TAU) or TAU.


Options:
A: Outcome Questionnaire -45.2 (Lambert et al., 2004) (3 months)
B: Number of repeated self-harming acts including suicide attempts (change in number of self-harming acts). (Week 0 (baseline), 17, 28, 52.)
C: The acceptability of the intervention to patients (within 6 months of study completion); The feasibility of intervention delivery at the ER setting (within 6 months of study completion); Patient recruitment (Baseline); The proportion of participating patients who can be reached by telephone contact at the 3-month follow-up. (3 months); The proportion of participating patients who can be reached by telephone contact at the 6-month follow-up. (6 months); The proportion of participating patients who can be traced from the hospital record at the 3-month. (3 months); The proportion of participating patients who can be traced from the hospital record at the 6-month. (6 months); The proportion of participating patients whose identity card number can be linked to the nationwide self-harm registry at the 6-month. (6 months); The proportion of participating patients whose identity card number can be linked to the nationwide self-harm registry at the 3-month. (3 months); Change in scores on a self-report suicidal behaviors assessment from baseline to 3 months (Baseline, 3 months); Change in scores on a self-report suicidal behaviors assessment from baseline to 6 months (Baseline, 6 months); Number of repeat self-harm episodes per person in 3 months after intervention based on hospital records (3 months); Number of repeat self-harm episodes per person in 3 months after intervention recorded in the nationwide self-harm registry (3 months); Number of repeat self-harm episodes per person in 6 months after intervention based on hospital records (6 months); Number of repeat self-harm episodes per person in 6 months after intervention recorded in the nationwide self-harm registry (6 months); Time to next self-harm repetition (in days) following randomization (6 months)
D: Number of days with hospital admission (Change between the period from 12 month retrospectively to Baseline and the period from baseline to 12 months prospectively)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Harvest for Health in Older Cancer Survivors
Brief Summary: Gardening interventions yield a multitude of measurable benefits that are evaluable within the context of a clinical trial. Harvest for Health forges new inroads in the delivery of holistic interventions to high risk populations, in this case, older cancer survivors. Since the intervention banks on an existing organization's infrastructure, it can easily be disseminated nationwide. The next step is to prove efficacy - an essential step in contributing to the science in this area, and one which is crucial for future dissemination.


Options:
A: Proportion of individuals receiving a standardized program of pretest education who then proceed to genetic testing (Up to 1 year); Proportions of individuals who choose to receive the results through their primary care providers or through the study-provided expert staff (Up to 1 year); Psychosocial impact of genetic population screening utilizing a digital health solution (Up to 1 year); Facilitators and barriers to engaging primary care providers (PCPs) in the BRCA1/2 results disclosure process (Up to 1 year); Participant health updates in personal familial cancer diagnosis and genetic testing depending on method of results communication (Up to 1 year)
B: Proportion of respondents who will complete the 3-month follow-up (Finish all telephone survey by Jan 2018)
C: Percent of subjects in each group at year 1 who meet ALL 3 of 3 of the following goals: Physical performance tests, plasma α-carotene, and accelerometry-measured physical exam (1 year after baseline)
D: Adherence Rates to various methods of daily survey administration (35 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: The Effect of Oral Zinc Supplementation on Thiol Oxido-reductive Index and Thiol Related Enzymes in Spermatozoa of Iraqi Asthenospermic Patients
Brief Summary: Although several studies have considered the relationship between infertility and semen thiol compounds levels, no study on the effects of asthenospermia treatments such as oral zinc supplementation on thiol related enzymes activity which are important in fertility of the individual has been reported.


Options:
A: DFI_3 (Change in DNA Fragmentation Index from Baseline to 3 months); DFI_6 (Change in DNA Fragmentation Index from Baseline to 6 months)
B: Live Birth (At delivery); Semen Volume (6 months); Sperm Concentration (6 months); Sperm Motility (6 months); Sperm Morphology (6 months); DNA Fragmentation Index (6 months); Total Motile Sperm Count (6 months)
C: Thiol oxido-reductive index levels in spermatozoa and seminal plasma. The investigators evaluated the effects of zinc sulfate (220 mg/d) supplementation on Thiol oxido-reductive index levels. (up to three months.)
D: Effect of resveratrol on oocyte quality (40 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Brief Summary: The objective of this Randomised Controlled Trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) including STRIP assistant (STRIPA) implemented by an appropriately qualified team will lead to an improvement in clinical and economic outcomes among patients aged 70 years and more with multimorbidity and polypharmacy.


Options:
A: Patients with confirmed DRA after discharge from the index hospitalisation (12 months)
B: Medication adherence assessment method (one month)
C: Medication possession ratio (MPR), gaps and persistence in medicines use (Seven months after recruitment)
D: Changes in decisional conflict (baseline and 3 month post intervention)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Brief Summary: The objective of this Randomised Controlled Trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) including STRIP assistant (STRIPA) implemented by an appropriately qualified team will lead to an improvement in clinical and economic outcomes among patients aged 70 years and more with multimorbidity and polypharmacy.


Options:
A: Health-related quality of life (6 months)
B: N/A
C: Patients with confirmed DRA after discharge from the index hospitalisation (12 months)
D: number of unplanned hospitalizations (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial
Brief Summary: The objective of this Randomised Controlled Trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP) including STRIP assistant (STRIPA) implemented by an appropriately qualified team will lead to an improvement in clinical and economic outcomes among patients aged 70 years and more with multimorbidity and polypharmacy.


Options:
A: Patients with confirmed DRA after discharge from the index hospitalisation (12 months)
B: Hospital readmission (30 days)
C: Goal Attainment Scaling at 3 months (3 months)
D: The evolution of the level of functional autonomy of the patients assessed using the scale IADL of Lawton (At inclusion); The evolution of the level of functional autonomy of the patients assessed using the scale IADL of Lawton (At 1 month); The evolution of the level of functional autonomy of the patients assessed using the scale IADL of Lawton (At 6 months); The evolution of the level of functional autonomy of the patients assessed using the scale IADL of Lawton (At 18 months); The evolution of the level of functional autonomy of the patients assessed using the scale DAD-6. (At inclusion); The evolution of the level of functional autonomy of the patients assessed using the scale DAD-6. (At 1 month); The evolution of the level of functional autonomy of the patients assessed using the scale DAD-6. (At 6 months); The evolution of the level of functional autonomy of the patients assessed using the scale DAD-6. (At 18 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Brief Summary: The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).


Options:
A: Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57 (Up to 6 hours post dose on Day 57)
B: Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52) (Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52))
C: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) (Baseline, Week 6)
D: Change from baseline in the average Hemoglobin (Hb) (Baseline and Weeks 18 to 24)

Answer: D